IL1B and diabetes mellitus: The massive release of downstream inflammatory cytokines (IL-1β and IL-18) directly affects the host’s innate immune regulation to infection and injury, induces acute and chronic inflammatory responses, and participates in the occurrence and development of these diseases, such as skin diseases, chronic kidney disease, cardiovascular diseases, neuronal diseases, and diabetes mellitus (Sharma et al., 2019).